Industry Watch [to 15 November 2014]
Selected media releases and other selected content from industry.
:: Sanofi launches paediatric vaccine Shan5 in India
Business Standard | 10 November 2014
With the launch of Shan 5 in India 27 million babies born annually will have access to vaccination
Hyderabad, November 10, 2014
Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday the launch of Shan5, its paediatric pentavalent vaccine developed and manufactured by its affiliate Shatha Biotechnic in India.
The vaccine received prequalification status from World Health Organisation (WHO) in April 2014.
“A significant number of babies born every year in India do not have access to modern vaccination programmes. The launch of Shan 5 in India means that 27 million babies born annually in India will have access to vaccination to protect from five potentially deadly diseases. By launching the vaccine Shantha will be contributing to filling this immunisation gap for the benefit of babies and their parents,” Harish Iyer, CEO of Hyderabad-based Shantha said…
:: Hilleman Laboratories signs MoU to fast track development of high-impact Oral Cholera Vaccine
10/11/2014
Hilleman Laboratories, an equal joint-venture partnership between Merck & Co. and Wellcome Trust, has signed a Memorandum of Understanding (MoU) with Bangladesh-based icddr,b (formerly the International Centre for Diarrheal Disease Research, Bangladesh), an international public health research organization, and Incepta Vaccine Ltd., leading pharmaceutical company in Bangladesh in a bid to fast track the clinical trials and product licensing and commercialization of the product….
… Dr. John Clemens, Executive Director, icddr,b said, “Cholera is a major public health problem in several developing countries and we are excited to have the opportunity to translate research into prevention. An important challenge is to understand the effectiveness of vaccines in resource poor, high-risk settings. For a variety of reasons, responses to oral vaccines in the developing world are often lower than those seen in industrialized countries. Optimizing a vaccine candidate to fit such settings and saving lives is synonymous with our philosophy.”…